Phil Floucault - Isracann Biosciences Pres CEO
Insider
Phil Floucault is Pres CEO of Isracann Biosciences
| Age | 46 |
| Phone | 604 394 2551 |
| Web | https://www.isracann.com |
Isracann Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.3499) % which means that it has lost $0.3499 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.5275) %, meaning that it generated substantial loss on money invested by shareholders. Isracann Biosciences' management efficiency ratios could be used to measure how well Isracann Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Stephan Bankosz | Vext Science | N/A | |
| Jennifer Drake | AYR Strategies Class | N/A | |
| Brett Summerer | Verano Holdings Corp | 46 | |
| David Goubert | AYR Strategies Class | N/A | |
| Sarvesh Mathur | AYR Strategies Class | N/A | |
| James Mendola | AYR Strategies Class | N/A | |
| Jonathan JD | AYR Strategies Class | 65 | |
| John Tipton | Verano Holdings Corp | 62 | |
| Eric Offenberger | Vext Science | N/A | |
| Paul Fisher | AYR Strategies Class | N/A | |
| Aaron Miles | Verano Holdings Corp | 44 | |
| Samuel Dorf | Verano Holdings Corp | N/A | |
| Brad Asher | AYR Strategies Class | N/A | |
| Yosuke Akita | Eisai Co | 58 | |
| Jeff Finnerty | AYR Strategies Class | N/A | |
| MD FAAN | Eisai Co | 73 | |
| Jonathan Ross | Vext Science | N/A | |
| David Spreckman | Verano Holdings Corp | 33 | |
| Nadeem Sarwar | Eisai Co | N/A | |
| Julianna CFA | Verano Holdings Corp | N/A | |
| Destiny Thompson | Verano Holdings Corp | 42 | |
Management Performance
| Return On Equity | -2.53 | |||
| Return On Asset | -0.35 |
Isracann Biosciences Leadership Team
Elected by the shareholders, the Isracann Biosciences' board of directors comprises two types of representatives: Isracann Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Isracann. The board's role is to monitor Isracann Biosciences' management team and ensure that shareholders' interests are well served. Isracann Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Isracann Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Thompson, Chief Officer | ||
| Matthew Chatterton, Chief Officer | ||
| Phil Floucault, Pres CEO | ||
| Yana CPA, Corp CFO |
Isracann Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Isracann Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.53 | |||
| Return On Asset | -0.35 | |||
| Current Valuation | 2.16 M | |||
| Shares Outstanding | 175.99 M | |||
| Shares Owned By Insiders | 0.50 % | |||
| Price To Book | 9.57 X | |||
| Price To Sales | 8.83 X | |||
| EBITDA | (4.64 M) | |||
| Net Income | (4.69 M) | |||
| Cash And Equivalents | 310.61 K |
Currently Active Assets on Macroaxis
Other Information on Investing in Isracann Pink Sheet
Isracann Biosciences financial ratios help investors to determine whether Isracann Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Isracann with respect to the benefits of owning Isracann Biosciences security.